ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
120.766,57
0,00%
S&P 500
6.040,04
1,10%
US Dollar vs BRL
6,7426
0,13%
Bitcoin
95.517,12
-3,81%
Brent Oil
73,565
0,38%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. KalVista Pharmaceuticals Inc (KALV)

  7. KalVista Pharmaceuticals Inc (KALV) Notícias

KALV

KalVista Pharmaceuticals (KALV)

KalVista Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:KALV
DataHoraFonteTítuloCódigoCompanhia
16/12/202409:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
16/12/202409:00Business WireKalVista Appoints Jeb Ledell as Chief Operating OfficerNASDAQ:KALVKalVista Pharmaceuticals Inc
09/12/202423:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
05/12/202418:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KALVKalVista Pharmaceuticals Inc
05/12/202408:30Business WireKalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational UpdateNASDAQ:KALVKalVista Pharmaceuticals Inc
04/12/202408:30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
26/11/202418:39Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
26/11/202409:00Business WireKalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of DirectorsNASDAQ:KALVKalVista Pharmaceuticals Inc
14/11/202417:57Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KALVKalVista Pharmaceuticals Inc
14/11/202414:02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KALVKalVista Pharmaceuticals Inc
12/11/202408:30Business WireKalVista Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:KALVKalVista Pharmaceuticals Inc
07/11/202416:34Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:KALVKalVista Pharmaceuticals Inc
04/11/202409:05Business WireKalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 MillionNASDAQ:KALVKalVista Pharmaceuticals Inc
04/11/202409:00Business WireKalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare TrustNASDAQ:KALVKalVista Pharmaceuticals Inc
28/10/202407:30Business WireKalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and ImmunologyNASDAQ:KALVKalVista Pharmaceuticals Inc
18/10/202407:30Business WireKalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)NASDAQ:KALVKalVista Pharmaceuticals Inc
04/10/202413:29Business WireKalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema ForumNASDAQ:KALVKalVista Pharmaceuticals Inc
30/09/202407:30Business WireKalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
26/09/202407:30Business WireKalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)NASDAQ:KALVKalVista Pharmaceuticals Inc
10/09/202408:00Business WireKalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:KALVKalVista Pharmaceuticals Inc
10/09/202407:30Business WireKalVista Appoints Brian Piekos as Chief Financial OfficerNASDAQ:KALVKalVista Pharmaceuticals Inc
06/09/202407:30Business WireKalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024NASDAQ:KALVKalVista Pharmaceuticals Inc
05/09/202407:30Business WireKalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational UpdateNASDAQ:KALVKalVista Pharmaceuticals Inc
03/09/202407:30Business WireKalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
29/08/202407:30Business WireKalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin SymposiumNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202417:17Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202417:13Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202417:08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KALVKalVista Pharmaceuticals Inc
15/08/202407:30Business WireKalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
22/07/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KALVKalVista Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:KALV

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados